...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of gastroenterology and hepatology >The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study.
【24h】

The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study.

机译：舒林酸对原发性对熊去氧胆酸反应不完全的原发性胆汁性肝硬化患者的影响：一项初步研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVES: In 30% of patients with primary biliary cirrhosis (PBC) ursodeoxycholic acid (UDCA) causes full biochemical normalization, while 70% are incomplete responders. The only differences between the two groups are the significantly higher cholestasis indices in the incomplete responders. In these patients we investigated whether the strongly choleretic sulindac together with UDCA is superior to UDCA monotherapy. DESIGN AND METHODS: Twenty-three patients with PBC incompletely responding to UDCA monotherapy were entered in the open label study for 12 months. Eleven patients (stage II, seven; III, two; and IV, two) received UDCA (10-15 mg/kg/day) plus sulindac (100-300 mg/day) (Group I). Twelve patients (stage I, six; II, four; III, one; and IV, one) were treated with UDCA alone (Group II). Liver biochemistry, analysis of antimitochondrial, antinuclear, smooth muscle, and liver-kidney-microsomal antibodies, ultrasonography and gastroscopy were done in regular intervals. RESULTS: In Group I all liverindices, IgG, IgM and IgA significantly improved although pretreatment data and stages of the disease tended to be higher than in Group II. In five patients of Group I liver histology improved slightly. Sulindac was well tolerated. The biochemical indices did not further improve on UDCA monotherapy. CONCLUSIONS: Sulindac in combination with UDCA further improves liver biochemistries in patients with PBC who responded incompletely to UDCA alone.
机译：目的：在原发性胆汁性肝硬化（PBC）的患者中，有30％的熊去氧胆酸（UDCA）引起完全的生化正常化，而70％的患者是不完全应答者。两组之间的唯一区别是在不完全应答者中胆汁淤积指数明显更高。在这些患者中，我们研究了强胆性舒灵酸与UDCA联合治疗是否优于UDCA单药治疗。设计与方法：23例对UDCA单药治疗不完全反应的PBC患者进入开放标签研究，为期12个月。 11例患者（II期，七期; III期，两个; IV期，两个）接受UDCA（10-15 mg / kg /天）加舒林酸（100-300 mg /天）（I组）。 12名患者（I期，六期; II期，四期; III期，一期; IV期，一期）仅接受UDCA治疗（第二组）。定期进行肝生化分析，抗线粒体，抗核，平滑肌和肝肾微粒体抗体分析，超声检查和胃镜检查。结果：尽管治疗前数据和疾病分期往往比第二组更高，但在第一组中所有肝指标，IgG，IgM和IgA均显着改善。在第一组的五名患者中，肝脏组织学略有改善。舒林酸的耐受性良好。 UDCA单药治疗的生化指标没有进一步改善。结论：舒林酸联合UDCA可进一步改善仅对UDCA反应不完全的PBC患者的肝脏生物化学。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号